Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027
Details : Results of Phase 1 clinical trials showed no serious adverse events with infusion of TY027 in healthy volunteers, and researchers evaluated up to the 30 mg/kg dose.
Product Name : TY027
Product Type : Antibody
Upfront Cash : Inapplicable
October 12, 2020
Lead Product(s) : TY027
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable